In vivo knockdown of pathogenic proteins via specific and nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent protein erasers (SNIPERs)

Journal of Biological Chemistry

Volumn 292, Issue 11, 2017, Pages 4556-4570

  Ohoka, Nobumichi ^a   Okuhira, Keiichiro ^a,c   Ito, Masahiro ^b   Nagai, Katsunori ^b   Shibata, Norihito ^a   Hattori, Takayuki ^a   Ujikawa, Osamu ^b   Shimokawa, Kenichiro ^b   Sano, Osamu ^b   Koyama, Ryokichi ^b   Fujita, Hisashi ^b   Teratani, Mika ^b   Matsumoto, Hirokazu ^b   Imaeda, Yasuhiro ^b   Nara, Hiroshi ^b   Cho, Nobuo ^b   Naito, Mikihiko ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; ENZYME INHIBITION; ENZYMES; LIGANDS; MOLECULES; TUMORS;

INHIBITOR OF APOPTOSIS PROTEINS; PATHOGENIC PROTEINS; PHOSPHODIESTERASE-4; PROTEASOMAL DEGRADATION; SELECTIVE DEGRADATION; SPECIFIC INHIBITORS; THERAPEUTIC ACTIVITY; THERAPEUTIC EFFECTS;

PROTEINS;

BCR ABL PROTEIN; BRD4 PROTEIN; ESTROGEN RECEPTOR ALPHA; IAP1 PROTEIN; INHIBITOR OF THE APOPTOSIS PROTEIN; PHOSPHODIESTERASE IV; PROTEASOME; PROTEIN INHIBITOR; REGULATOR PROTEIN; SNIPER PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR ALPHA, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; LIGAND;

ARTICLE; BINDING AFFINITY; BIOTECHNOLOGY; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN CELL; IN VIVO STUDY; PROTEIN DEGRADATION; TUMOR XENOGRAFT; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST; BREAST TUMOR; CELL LINE; DRUG DEVELOPMENT; DRUG EFFECTS; FEMALE; METABOLISM; MOLECULAR LIBRARY; MOUSE; NUDE MOUSE; PATHOLOGY; PHARMACOLOGY; THERAPEUTIC USE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; DRUG DISCOVERY; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIGANDS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; SMALL MOLECULE LIBRARIES; UBIQUITINATION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 85015296681     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.768853     Document Type: Article

References (40)

1. Zhang, J., Yang, P. L., and Gray, N. S. (2009) Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39
2. Wells, J. A., and McClendon, C. L. (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009
3. Arkin, M. R., and Wells, J. A. (2004) Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev. Drug Discov. 3, 301-317
4. Mansoori, B., Sandoghchian Shotorbani, S., and Baradaran, B. (2014) RNA interference and its role in cancer therapy. Adv. Pharm. Bull. 4, 313-321
5. Ozcan, G., Ozpolat, B., Coleman, R. L., Sood, A. K., and Lopez-Berestein, G. (2015) Preclinical and clinical development of siRNA-based therapeutics. Adv. Drug Deliv. Rev. 87, 108-119
6. Ohoka, N., Shibata, N., Hattori, T., and Naito, M. (2016) Protein knockdown technology: application of ubiquitin ligase to cancer therapy. Curr. Cancer Drug Targets 16, 136-146
7. Toure, M., and Crews, C. M. (2016) Small-molecule PROTACS: new approaches to protein degradation. Angew. Chem. Int. Ed. Engl. 55, 1966-1973
8. Bondeson, D. P., Mares, A., Smith, I. E., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., Zinn, N., Grandi, P., Shimamura, S., Bergamini, G., Faelth-Savitski, M., et al. (2015) Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611-617
9. Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., and Crews, C. M. (2015) Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755-763
10. Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., and Bradner, J. E. (2015) Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376-1381
11. Itoh, Y., Ishikawa, M., Naito, M., and Hashimoto, Y. (2010) Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. J. Am. Chem. Soc. 132, 5820-5826
12. Okuhira, K., Ohoka, N., Sai, K., Nishimaki-Mogami, T., Itoh, Y., Ishikawa, M., Hashimoto, Y., and Naito, M. (2011) Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that cross-link cIAP1 and the target protein. FEBS Lett. 585, 1147-1152
13. Demizu, Y., Okuhira, K., Motoi, H., Ohno, A., Shoda, T., Fukuhara, K., Okuda, H., Naito, M., and Kurihara, M. (2012) Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy. Bioorg. Med. Chem. Lett. 22, 1793-1796
14. Okuhira, K., Demizu, Y., Hattori, T., Ohoka, N., Shibata, N., Nishimaki-Mogami, T., Okuda, H., Kurihara, M., and Naito, M. (2013) Development of hybrid small molecules that induce degradation of estrogen receptor-α and necrotic cell death in breast cancer cells. Cancer Sci. 104, 1492-1498
15. Ohoka, N., Nagai, K., Hattori, T., Okuhira, K., Shibata, N., Cho, N., and Naito, M. (2014) Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway. Cell Death Dis. 5, e1513
16. Sekine, K., Takubo, K., Kikuchi, R., Nishimoto, M., Kitagawa, M., Abe, F., Nishikawa, K., Tsuruo, T., and Naito, M. (2008) Small molecules destabilize cIAP1 by activating autoubiquitylation. J. Biol. Chem. 283, 8961-8968
17. Fulda, S., and Vucic, D. (2012) Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 11, 109-124
18. Deveraux, Q. L., and Reed, J. C. (1999) IAP family proteins-suppressors of apoptosis. Genes Dev. 13, 239-252
19. Salvesen, G. S., and Duckett, C. S. (2002) IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 3, 401-410
20. Deveraux, Q. L., Takahashi, R., Salvesen, G. S., and Reed, J. C. (1997) X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388, 300-304
21. Hao, Y., Sekine, K., Kawabata, A., Nakamura, H., Ishioka, T., Ohata, H., Katayama, R., Hashimoto, C., Zhang, X., Noda, T., Tsuruo, T., and Naito, M. (2004) Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat. Cell Biol. 6, 849-860
22. Suzuki, Y., Nakabayashi, Y., and Takahashi, R. (2001) Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc. Natl. Acad. Sci. U.S.A. 98, 8662-8667
23. Kikuchi, R., Ohata, H., Ohoka, N., Kawabata, A., and Naito, M. (2014) APOLLON protein promotes early mitotic CYCLIN A degradation independent of the spindle assembly checkpoint. J. Biol. Chem. 289, 3457-3467
24. Imoto, I., Tsuda, H., Hirasawa, A., Miura, M., Sakamoto, M., Hirohashi, S., and Inazawa, J. (2002) Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res. 62, 4860-4866
25. Imoto, I., Yang, Z. Q., Pimkhaokham, A., Tsuda, H., Shimada, Y., Imamura, M., Ohki, M., and Inazawa, J. (2001) Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res. 61, 6629-6634
26. Tamm, I., Kornblau, S. M., Segall, H., Krajewski, S., Welsh, K., Kitada, S., Scudiero, D. A., Tudor, G., Qui, Y. H., Monks, A., Andreeff, M., and Reed, J. C. (2000) Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 6, 1796-1803
27. Cohen, P., and Tcherpakov, M. (2010) Will the ubiquitin system furnish as many drug targets as protein kinases? Cell 143, 686-693
28. Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J., Flygare, J. A., Fairbrother, W. J., Deshayes, K., Dixit, V. M., and Vucic, D. (2007) IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131, 669-681
29. Vince, J. E., Wong, W. W., Khan, N., Feltham, R., Chau, D., Ahmed, A. U., Benetatos, C. A., Chunduru, S. K., Condon, S. M., McKinlay, M., Brink, R., Leverkus, M., Tergaonkar, V., Schneider, P., Callus, B. A., et al. (2007) IAP antagonists target cIAP1 to induce TNFô-dependent apoptosis. Cell 131, 682-693
30. Bertrand, M. J., Milutinovic, S., Dickson, K. M., Ho, W. C., Boudreault, A., Durkin, J., Gillard, J. W., Jaquith, J. B., Morris, S. J., and Barker, P. A. (2008) cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30, 689-700
31. Hall, J. M., and McDonnell, D. P. (2005) Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol. Interv. 5, 343-357
32. Nadji, M., Gomez-Fernandez, C., Ganjei-Azar, P., and Morales, A. R. (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am. J. Clin. Pathol. 123, 21-27
33. Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M., Wang, J., Chen, X., Dong, H., Siu, K., Winkler, J. D., Crew, A. P., Crews, C. M., and Coleman, K. G. (2016) PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 113, 7124-7129
34. Pedersen, J., LaCasse, E. C., Seidelin, J. B., Coskun, M., and Nielsen, O. H. (2014) Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. Trends Mol. Med. 20, 652-665
35. Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime-Figueroa, S., Ko, E., Hines, J., and Crews, C. M. (2016) Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew. Chem. Int. Ed. Engl. 55, 807-810
36. Katsuragi, Y., Ichimura, Y., and Komatsu, M. (2015) p62/SQSTM1 functions as a signaling hub and an autophagy adaptor. FEBS J. 282, 4672-4678
37. Thorslund, T., Ripplinger, A., Hoffmann, S., Wild, T., Uckelmann, M., Villumsen, B., Narita, T., Sixma, T. K., Choudhary, C., Bekker-Jensen, S., and Mailand, N. (2015) Histone H1 couples initiation and amplification of ubiquitin signalling after DNA damage. Nature 527, 389-393
38. Honsho, M., Yamashita, S., and Fujiki, Y. (2016) Peroxisome homeostasis: mechanisms of division and selective degradation of peroxisomes in mammals. Biochim. Biophys. Acta 1863, 984-991
39. Mohapatra, B., Ahmad, G., Nadeau, S., Zutshi, N., An, W., Scheffe, S., Dong, L., Feng, D., Goetz, B., Arya, P., Bailey, T. A., Palermo, N., Borgstahl, G. E., Natarajan, A., Raja, S. M., et al. (2013) Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochim. Biophys. Acta 1833, 122-139
40. Shibata, N., Ohoka, N., Sugaki, Y., Onodera, C., Inoue, M., Sakuraba, Y., Takakura, D., Hashii, N., Kawasaki, N., Gondo, Y., and Naito, M. (2015) Degradation of stop codon read-through mutant proteins via the ubiquitin-proteasome system causes hereditary disorders. J. Biol. Chem. 290, 28428-28437